Ampio Pharmaceuticals appoints Dan Stokely CFO
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common... Read More
Thursday July 11, 2019 0 comments
Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reported that the Phase 3 clinical trial of Ampion met its primary endpoint with 71% of Ampion treated patients meeting the... Read More
Friday December 15, 2017 0 comments
Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion
ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) today announced the allowance of an important composition and methods patent in the U.S. complimenting a series of patents on Ampion... Read More
Tuesday August 8, 2017 0 comments
Ampio initiates pivotal Ampion osteoarthritis trial
ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) announced it has begun a single injection study to meet the unmet medical need of treating the severe pain and loss of function... Read More
Monday May 1, 2017 0 comments
Ampio: FDA discussions continue on best path forward for Ampion
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it is continuing discussions with the CBER Division of the FDA to determine the best path forward to obtain a Biological... Read More
Thursday November 10, 2016 0 comments
Ampio Pharmaceuticals announces mostly positive results for Ampion
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT:AMPE) announced the results of the Ampion PIVOT clinical trial as well as a comprehensive analysis that integrates trial data from three single... Read More
Friday July 1, 2016 0 comments
Ampio Pharmaceuticals launches clinical trial of Ampion for treatment of osteoarthritis of the hand
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced patient dosing has begun in the initial clinical trial of Ampion for the treatment of pain due to osteoarthritis of the... Read More
Tuesday May 10, 2016 0 comments
Aytu adds two founders to board of directors
ENGLEWOOD -- Aytu BioScience, Inc .(OTCQX: AYTU), a specialty healthcare company focused on commercializing treatments for urological and related conditions, announced Josh Disbrow , Aytu''s... Read More
Thursday January 28, 2016 0 comments
- 1
- 2
IN Sponsors
Browse
Entrepreneurial by Nature
